摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-叔丁氧羰基-3-甲基-L-组氨酸 | 61070-22-2

中文名称
N-叔丁氧羰基-3-甲基-L-组氨酸
中文别名
甲基组胺酸;(S)-2-(Boc-氨基)-3-(1-甲基-5-咪唑基)丙酸
英文名称
Boc-His(ϖ-Me)-OH
英文别名
Boc-his(3-ME)-OH;(2S)-3-(3-methylimidazol-4-yl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid
N-叔丁氧羰基-3-甲基-L-组氨酸化学式
CAS
61070-22-2
化学式
C12H19N3O4
mdl
——
分子量
269.301
InChiKey
BGZFLUIZBZNCTI-VIFPVBQESA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    502.2±45.0 °C(Predicted)
  • 密度:
    1.23
  • 稳定性/保质期:
    避免接触水

计算性质

  • 辛醇/水分配系数(LogP):
    0.6
  • 重原子数:
    19
  • 可旋转键数:
    6
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.58
  • 拓扑面积:
    93.4
  • 氢给体数:
    2
  • 氢受体数:
    5

安全信息

  • 海关编码:
    2933290090

SDS

SDS:171a13a881c5ca19432b3dd66323e8f1
查看

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Design, Synthesis, and Optimization of Novel Epoxide Incorporating Peptidomimetics as Selective Calpain Inhibitors
    摘要:
    Hyperactivation of the calcium-dependent cysteine protease calpain 1 (Call) is implicated as a primary or secondary pathological event in a wide range of illnesses and in neurodegenerative states, including Alzheimer's disease (AD). E-64 is an epoxide-containing natural product identified as a potent nonselective, calpain inhibitor, with demonstrated efficacy in animal models of AD. By use of E-64 as a lead, three successive generations of calpain inhibitors were developed using computationally assisted design to increase selectivity for Call. First generation analogues were potent inhibitors, effecting covalent modification of recombinant Call catalytic domain (Call(cat)), demonstrated using LC-MS/MS. Refinement yielded second generation inhibitors with improved selectivity. Further library expansion and ligand refinement gave three Call inhibitors, one of which was designed as an activity-based protein profiling probe. These were determined to be irreversible and selective inhibitors by kinetics studies comparing full length Call with the genera l cysteine protease papain.
    DOI:
    10.1021/jm4006719
点击查看最新优质反应信息

文献信息

  • Backbone Modification of β-Hairpin-Forming Tetrapeptides in Asymmetric Acyl Transfer Reactions
    作者:Peng Chen、Jin Qu
    DOI:10.1021/jo200403g
    日期:2011.5.6
    acyl transfer reaction of trans-2-(N-acetylamino)cyclohexan-1-ol (krel = 28). Through our backbone modification strategy, thioamide and sulfonamide as the isosteres of amide were introduced in the β-hairpin secondary structure. The thioxo peptides also adopt β-hairpin conformations as the oxopeptide supported by the combined use of NMR, IR, and X-ray techniques. Thioxo tetrapeptide 14 formed a more
    合成的寡肽作为酶的模拟物已被越来越多地用作不对称反应的催化剂,但是仍然需要相对低分子量的高效寡肽催化剂。在本文中,我们展示了形成β-发夹的四肽4的构象工程,该构象是Miller小组首次报道的,它是反式-2-(N-乙酰氨基)环己-1-醇(不饱和)的不对称酰基转移反应的催化剂(ķ相对= 28)。通过我们的主链修饰策略,将硫代酰胺和磺酰胺作为酰胺的等排物引入了β-发夹二级结构中。thioxo肽还采用β-发夹结构作为氧肽,并结合使用NMR,IR和X射线技术来支持。硫氧四肽14形成了更受约束的β-发夹构象,因此在同一反应中提供了更高的对映选择性(k rel = 109)。此外,四肽的构象变化的检查8在所述的质子化Ñ π -methylhistidine部分提供了证据来解释在不对称酰基转移反应的催化效率的变化。
  • A Multicatalyst System for the One‐Pot Desymmetrization/Oxidation of <i>meso</i> ‐1,2‐Alkane Diols
    作者:Christian E. Müller、Radim Hrdina、Raffael C. Wende、Peter R. Schreiner
    DOI:10.1002/chem.201100498
    日期:2011.5.27
    Two is better than one: We demonstrate the viability of an organocatalytic reaction sequence along a short peptide backbone that carries two independent catalytic functionalities, which allow the rapid, onepot acylative desymmetrization and oxidation of mesoalkane1,2diols to the corresponding acetylated acetoins with good yields and enantioselectivities (see scheme).
    两个优于一个:我们证明的有机催化反应序列的沿着承载两个独立的催化功能,其允许快速,一锅acylative desymmetrization和氧化的短肽骨架的生存能力内消旋-烷烃-1,2-二醇来具有良好产率和对映选择性的相应乙酰化乙酰丙酮(参见方案)。
  • Site-Selective Acylation of Pyranosides with Oligopeptide Catalysts
    作者:Alexander Seitz、Raffael C. Wende、Emily Roesner、Dominik Niedek、Christopher Topp、Avene C. Colgan、Eoghan M. McGarrigle、Peter R. Schreiner
    DOI:10.1021/acs.joc.0c02772
    日期:2021.3.5
    monosaccharides. We identified catalysts that invert site-selectivity compared to N-methylimidazole, which was used to determine the intrinsic reactivity, for 4,6-O-protected glucopyranosides (trans-diols) as well as 4,6-O-protected mannopyranosides (cis-diols). The reaction yields up to 81% of the inherently unfavored 2-O-acetylated products with selectivities up to 15:1 using mild reaction conditions. We also
    在此,我们报道了部分保护的单糖的寡肽催化的位点选择性酰化。我们确定了催化剂,其反转的网站选择性相比ñ甲基咪唑,这是用来确定内在反应,为4,6- Ø重保护的吡喃葡萄糖苷(反式-diols)以及4,6- Ø -protected mannopyranosides(顺-二醇)。在温和的反应条件下,该反应产生高达81%的固有不利的2- O-乙酰化产物,选择性高达15:1。我们还确定了保护基对反应的影响,并证明我们的方案适用于具有多个连续保护步骤的一锅法反应。
  • Substituted hydantoins
    申请人:Goodnow, Alan Robert
    公开号:US20060063814A1
    公开(公告)日:2006-03-23
    The present invention relates to compounds of the formula which are useful in treating diseases characterized by the hyperactivity of MEK. Accordingly the compounds are useful in the treatment of diseases, such as, cancer, cognative and CNS disorders and inflammatory/autoimmune diseases.
    本发明涉及以下公式的化合物,这些化合物在治疗以MEK高活性为特征的疾病方面具有用途。因此,这些化合物在治疗癌症、认知和中枢神经系统疾病以及炎症/自身免疫疾病等疾病方面具有用途。
  • METHOD FOR INHIBITING PROLIFERATION OF TUMOR CELLS
    申请人:Niu Huifeng
    公开号:US20080207563A1
    公开(公告)日:2008-08-28
    Disclosed are methods for synergistically inhibiting the proliferation of tumor cells by contacting the tumor cells with a MEK inhibitor compound and erlotinib, either sequentially or simultaneously. Also disclosed are methods for inhibiting the proliferation of tumor cells in a human, by administering to the human, sequentially or simultaneously, an amount of erlotinib and a MEK inhibitor compound, wherein the amounts are effective, in combination, to synergistically inhibit the proliferation of the tumor cells in the human.
    本文揭示了通过将肿瘤细胞与MEK抑制剂化合物和厄洛替尼接触,无论是顺序地还是同时地,协同抑制肿瘤细胞增殖的方法。还揭示了通过向人体逐步或同时施用厄洛替尼和MEK抑制剂化合物的方法,其中这些量在组合时对于协同抑制人体内肿瘤细胞增殖是有效的。
查看更多

同类化合物

(甲基3-(二甲基氨基)-2-苯基-2H-azirene-2-羧酸乙酯) (±)-盐酸氯吡格雷 (±)-丙酰肉碱氯化物 (d(CH2)51,Tyr(Me)2,Arg8)-血管加压素 (S)-(+)-α-氨基-4-羧基-2-甲基苯乙酸 (S)-阿拉考特盐酸盐 (S)-赖诺普利-d5钠 (S)-2-氨基-5-氧代己酸,氢溴酸盐 (S)-2-[3-[(1R,2R)-2-(二丙基氨基)环己基]硫脲基]-N-异丙基-3,3-二甲基丁酰胺 (S)-1-(4-氨基氧基乙酰胺基苄基)乙二胺四乙酸 (S)-1-[N-[3-苯基-1-[(苯基甲氧基)羰基]丙基]-L-丙氨酰基]-L-脯氨酸 (R)-乙基N-甲酰基-N-(1-苯乙基)甘氨酸 (R)-丙酰肉碱-d3氯化物 (R)-4-N-Cbz-哌嗪-2-甲酸甲酯 (R)-3-氨基-2-苄基丙酸盐酸盐 (R)-1-(3-溴-2-甲基-1-氧丙基)-L-脯氨酸 (N-[(苄氧基)羰基]丙氨酰-N〜5〜-(diaminomethylidene)鸟氨酸) (6-氯-2-吲哚基甲基)乙酰氨基丙二酸二乙酯 (4R)-N-亚硝基噻唑烷-4-羧酸 (3R)-1-噻-4-氮杂螺[4.4]壬烷-3-羧酸 (3-硝基-1H-1,2,4-三唑-1-基)乙酸乙酯 (2S,3S,5S)-2-氨基-3-羟基-1,6-二苯己烷-5-N-氨基甲酰基-L-缬氨酸 (2S,3S)-3-((S)-1-((1-(4-氟苯基)-1H-1,2,3-三唑-4-基)-甲基氨基)-1-氧-3-(噻唑-4-基)丙-2-基氨基甲酰基)-环氧乙烷-2-羧酸 (2S)-2,6-二氨基-N-[4-(5-氟-1,3-苯并噻唑-2-基)-2-甲基苯基]己酰胺二盐酸盐 (2S)-2-氨基-3-甲基-N-2-吡啶基丁酰胺 (2S)-2-氨基-3,3-二甲基-N-(苯基甲基)丁酰胺, (2S,4R)-1-((S)-2-氨基-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺盐酸盐 (2R,3'S)苯那普利叔丁基酯d5 (2R)-2-氨基-3,3-二甲基-N-(苯甲基)丁酰胺 (2-氯丙烯基)草酰氯 (1S,3S,5S)-2-Boc-2-氮杂双环[3.1.0]己烷-3-羧酸 (1R,4R,5S,6R)-4-氨基-2-氧杂双环[3.1.0]己烷-4,6-二羧酸 齐特巴坦 齐德巴坦钠盐 齐墩果-12-烯-28-酸,2,3-二羟基-,苯基甲基酯,(2a,3a)- 齐墩果-12-烯-28-酸,2,3-二羟基-,羧基甲基酯,(2a,3b)-(9CI) 黄酮-8-乙酸二甲氨基乙基酯 黄荧菌素 黄体生成激素释放激素 (1-5) 酰肼 黄体瑞林 麦醇溶蛋白 麦角硫因 麦芽聚糖六乙酸酯 麦根酸 麦撒奎 鹅膏氨酸 鹅膏氨酸 鸦胆子酸A甲酯 鸦胆子酸A 鸟氨酸缩合物